PARVG

Across TCGA pan-cancer cohorts, PARVG mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PARVG data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PARVG mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PARVG expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

COAD, PDAC, and HNSC are the cancer types where PARVG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	III,IV	0.750	1.000	.019	84	view →
PDAC	DFS	Quartile	II,III,IV	0.642	0.927	.009	23	view →
HNSC	DFS	Median	All	0.699	0.855	.020	9	view →
GBM	OS	Tertile	All	0.210	0.536	.003	6	view →
LUAD	DFS	Tertile	All	0.954	0.878	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PARVG–COAD (DFS)

Open the COAD breakdown →